Organon & Co. (NYSE:OGN) Reaches New 52-Week High – Should You Buy?

Shares of Organon & Co. (NYSE:OGN) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $13.60 and last traded at $13.5950, with a volume of 2403529 shares trading hands. The stock had previously closed at $13.55.

Analyst Ratings Changes

Several analysts have issued reports on OGN shares. Weiss Ratings lowered Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday. Zacks Research raised Organon & Co. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 14th. BNP Paribas Exane reiterated a “neutral” rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Finally, Piper Sandler raised shares of Organon & Co. from an “underweight” rating to a “neutral” rating and increased their target price for the stock from $5.00 to $14.00 in a report on Tuesday, April 28th. Five analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and an average target price of $11.40.

Organon & Co. Stock Performance

The stock has a market cap of $3.57 billion, a P/E ratio of 17.66, a PEG ratio of 1.26 and a beta of 1.55. The company has a debt-to-equity ratio of 8.43, a current ratio of 1.95 and a quick ratio of 1.42. The firm’s 50-day moving average price is $13.49 and its 200-day moving average price is $10.56.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Organon & Co.’s dividend payout ratio is 10.39%.

Institutional Investors Weigh In On Organon & Co.

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in Organon & Co. by 2.7% in the 4th quarter. Vanguard Group Inc. now owns 36,916,382 shares of the company’s stock worth $264,690,000 after acquiring an additional 987,979 shares during the last quarter. State Street Corp grew its holdings in shares of Organon & Co. by 2.8% in the fourth quarter. State Street Corp now owns 9,597,761 shares of the company’s stock valued at $68,816,000 after purchasing an additional 262,185 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Organon & Co. by 105.2% in the fourth quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock valued at $61,282,000 after purchasing an additional 4,394,814 shares in the last quarter. Private Management Group Inc. increased its position in Organon & Co. by 38.3% in the fourth quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock worth $31,169,000 after purchasing an additional 1,204,979 shares during the last quarter. Finally, UBS Group AG increased its position in Organon & Co. by 55.2% in the fourth quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock worth $30,795,000 after purchasing an additional 1,527,492 shares during the last quarter. 77.43% of the stock is owned by institutional investors.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.